Beckley Psytech

Initial findings from our proof-of-concept Phase IIa study of ELE-101 for Major Depressive Disorder shows that a single 10-minute infusion is well-tolerated, induces rapid and lasting antidepressant effects for up to 3 months, and allows patients to be ready for discharge in approximately 2 hours. Commenting on the news, Dr Rob Conley, Beckley Psytech’s Chief Scientific and Medical Officer, said: “These positive initial findings indicate that our innovative intravenous formulation has the potential to provide an effective and rapid-acting treatment option for those suffering from depression, with a good safety and tolerability profile and lasting effects from a single dose. Whilst this was a small, proof-of-concept study, we are greatly encouraged by the results and we are looking forward to planning larger studies of ELE-101 in the coming months.” Learn more about the study, and our future plans, here: https://lnkd.in/ewiHM25H

🧠 How are next-generations psychedelics transforming mental health care? In this fascinating episode of The Healthtech Podcast with Dr. James Somauroo, our CEO, Cosmo Feilding Mellen, explores the science, safety, and societal impact behind psychedelic-based therapies. Whether you're curious about the future of mental health or want to understand the clinical landscape, tune in to learn more about the work we're doing to develop effective, rapid-acting and accessible medicines for people in need. 🎧 Listen here: https://lnkd.in/etJ4ayjk

ICYMI: Our CEO, Cosmo Feilding Mellen, caught up with TIME to discuss how our novel short-acting, psychedelic-based therapies could revolutionise the treatment of mental health conditions. Learn more here: https://lnkd.in/grJTzNWg

"I believe, in a decade from now, multiple psychedelics will be prescribed as legal medicines for a whole range of psychiatric conditions". In this fascinating interview with Evan Baehr, Beckley Psytech's CEO, Cosmo Feilding Mellen, shares his unique journey from growing up at the heart of the psychedelic revolution to leading the charge in plant-based medicine for conditions like depression and substance abuse. If you're curious about the future of mental health, tune in to learn more. https://lnkd.in/etNEk2Vr

How do you progress a psychedelic-based treatment through development and onto patients in need? That's what our Founder and CEO, Cosmo Feilding Mellen, discussed with Brandon Li on the 'Power to the Patients' podcast, where he covered everything from why shorter treatment duration matters to ethics in psychedelic medicines. Full episode in the comments.

Check out our CEO, Cosmo Feilding Mellen on the ‘Power to the Patients’ podcast where he talks about: 🌱 The founding story of Beckley Psytech 🚀 Our mission to develop effective and accessible medicines for mental health conditions and why we're focusing on next-generation compounds. 🧠 Our recent study results that show a single dose of our lead compound, BPL-003, can produce rapid and lasting effects for people with depression. Click through to listen here: https://lnkd.in/ecpWxput

On #WorldMentalHealthDay, we sat down with our Chief Scientific and Medical Officer, Dr. Rob Conley, to explore the current treatment landscape for mental health conditions and hear his hopes for the next generation of therapies. In this insightful Q+A, he draws on his experience from Beckley Psytech, Eleusis and Eli Lilly and Co, as well as his long academic career at the University of Pittsburgh and University of Maryland School of Medicine, to shed light on: 💊 The challenges with conventional mental health treatments 🧠 Advances in mental health care ✅ The potential of next-generation psychedelic-based solutions Click here to read the full Q+A and learn more about the evolving world of mental health treatments: https://lnkd.in/e6PRxgpf

How might next-generation psychedelics revolutionise mental health treatment? That's exactly what our CEO, Cosmo Feilding Mellen, discussed with Jamie Ducharme at TIME in this piece about the growing psychedelic medicine field. We're proud to be at the forefront of developing effective, rapid-acting and accessible medicines for conditions like depression and substance use disorders. Learn more about our work here: https://lnkd.in/grJTzNWg

Last month, our CEO, Cosmo Feilding Mellen, sat down with Brandon Li, Co-Founder of Power, the Modern Clinical Trial Marketplace, to talk about giving ‘Power to the Patients’. With nearly 1 billion people around the world living with a mental health disorder, and many of them not getting the relief they need from existing medications, we’re on a mission to develop effective, well-tolerated and accessible medicines that deliver rapid and lasting effects with a short time in clinic. Here's a sneak peak of the chat and tune in next week to learn more...

Today, we’re at #ECNP2024 sharing data from our open-label Phase IIa study which investigated the effects of BPL-003, our novel synthetic formulation of 5-MeO-DMT benzoate, in patients with Treatment Resistant Depression. Initial findings from that study showed that: 1) A single administration of BPL-003 demonstrated a rapid antidepressant effect, with 55% of patients having a 50% or greater improvement in depression symptoms the day after dosing (day 2). 2) BPL-003 could produce a robust and lasting antidepressant effect, with 55% of patients meeting the criteria for remission from symptoms of depression at day 29 and 45% in remission at day 85. 3) BPL-003 required a short time in clinic, with patients deemed dischargeable within an average time of less than 2 hours. With several Phase II studies underway investigating BPL-003 further in Treatment Resistant Depression and Alcohol Use Disorder, we are looking forward to learning more about how this novel compound could help people living with mental health conditions. Learn more about our Phase IIa findings and ongoing studies on our website: https://lnkd.in/g4QaUMAC #ECNP2024 #neuroscience #psychiatry